AbbVie Inc. (NYSE:ABBV) will present data evaluating three investigational compounds from the company’s oncology pipeline at the upcoming 56th American Society of Hematology Annual Meeting (ASH), December 6-9, in San Francisco. Data will be highlighted in 13 accepted abstracts, including several oral presentations detailing new trial results from the venetoclax program in acute myelogenous leukemia, elotuzumab in multiple myeloma, and duvelisib in patients with chronic … Continue reading Don’t Miss: AbbVie Inc. (NYSE:ABBV), Occidental Petroleum Corporation (NYSE:OXY), Quaker Chemical Corporation (NYSE:KWR), Issuer Direct Corporation (NYSEMKT:ISDR), Sirius XM Holdings Inc. (NASDAQ:SIRI)